UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
(Exact name of Registrant as Specified in its Charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
(Address of principal executive offices) (Zip Code) |
Registrant’s telephone number, including area code:
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02 | Results of Operations and Financial Condition |
On May 16, 2022, IO Biotech, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2022 and an update on the Company’s operations for the same period. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1.
In accordance with General Instruction B.2 of Form 8-K, the information included in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
Exhibit No. |
Description | |
99.1 | Press Release of the Company, dated May 16, 2022 | |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
IO BIOTECH, INC. | ||||||
Date: May 16, 2022 | By: | /s/ Mai-Britt Zocca | ||||
Name: | Mai-Britt Zocca, Ph.D. | |||||
Title: | Chief Executive Officer |
Exhibit 99.1
IO Biotech Announces First Quarter Results for 2022
Updated Data from Phase 1/2 study of IO102-IO103 in Combination with Nivolumab Showing High Response Rates in Metastatic Melanoma Presented at AACR in April
Announced initiation and dosing of first patient in Phase 2 Trial of IOB102-IOB103 in combination with KEYTRUDA® (pembrolizumab) as first line treatment in multi-arm basket trial
Strong Balance Sheet with ~$188 million Cash Runway to Support Multiple Data readouts into mid-2024
New York, New York May 16, 2022: IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced today financial results for the quarter ended March 31, 2022.
During our first quarter and in recent weeks we continued to advance our promising pipeline of immune-modulating cancer therapies, highlighted by the initiation of our IOB-022 / KN-D38 Phase 2 Trial, said Mai-Britt Zocca, Ph.D., President and Chief Executive Officer of IO Biotech. This trial will evaluate IOB102-103 with KEYTRUDA® (pembrolizumab) in previously untreated patients with three different tumor types in the first line setting, and we look forward to expanding our data set in these additional indications. We were also pleased to see the presentation of updated efficacy data and subgroup analyses from our MM1636 Phase 1/2 clinical trial evaluating IO102-IO103 as investigational agents in metastatic melanoma at the AACR annual meeting in April. These data further demonstrate the three-year survival probability of 73% for 3% for IO102-IO103 in combination with nivolumab for these patients, and we are encouraged by the clinical activity demonstrated in this trial. As previously disclosed, we expect to provide guidance regarding the timing for the interim readout for our IOB-013/KN-D18 Phase 3 trial towards the middle of this year. We believe our platform and product candidates may represent a paradigm shift in the management of cancer, and with a solid balance sheet we have a substantial cash runway to carry us through multiple data readouts into mid-2024.
Highlights for First Quarter 2022 and Recent Weeks
| Hosted Part 1 of Key Opinion Leader Webinar Series: A New Way to Kill TumorsIO102-IO103 Phase 3 Trial in Combination with Anti-PD-1 in Advanced Melanoma |
| Announced initiation and dosing of first patient in Phase 2 IOB-022 / KN-D38 trial (NCT05077709) |
| New data from MM1636 Phase 1/2 Clinical Trial presented at 2022 AACR Annual Meeting |
| Three-year Survival Probability of 73% |
| Subgroup analyses including patients with poor prognosis |
| David V. Smith Appointed to Board of Directors |
First Quarter Financial Results
| Net loss for the three months ended March 31, 2022 was $17.2 million, compared to $3.7 million for the quarter ended March 31, 2021. |
| Research and development expenses were $10.3 million for the three months ended March 31, 2022, compared to $2.8 million for the three months ended March 31, 2021. The increase of $7.5 million was primarily related to an increase in costs for chemistry, manufacturing and control, or CMC, activities of $2.3 million, an increase in personnel costs of $2.4 million primarily related to an increase in headcount and related recruiting costs and an increase in clinical trial-related activities for our IO102-IO103 product candidate, including the completion of our Phase 1/2 clinical studies, of $2.4 million. |
| General and administrative expenses were $6.7 million for the three months ended March 31, 2022, compared to $1.0 million for the three months ended March 31, 2021. The increase of $5.7 million was primarily related to an increase in professional services of $1.4 million related primarily to corporate legal fees and audit and tax fees and other consulting costs in support of our growth as well as an increase in personnel costs of $1.6 million primarily related to an increase in headcount and related recruiting costs and an increase in consultants and other costs of $2.7 million. |
| Cash and cash equivalents at March 31, 2022 were $187.9 million, compared to $211.5 million at December 31, 2021. Cash on hand is expected to support operations through anticipated data readouts into mid-2024. |
About the IOB-013 / KN-D18 Clinical Trial
IOB-013 / KN-D18 (Clinical Trials.gov: NCT05155254) is an open label, randomized Phase 3 clinical trial being conducted in collaboration with Merck of IO102-IO103 in combination with pembrolizumab versus pembrolizumab alone in patients with previously untreated, unresectable or metastatic (advanced) melanoma. Target enrollment will be 300 patients from centers spread across Europe, Australia, and the United States. Biomarker analyses will also be conducted. IO Biotech will sponsor the Phase 3 trial and Merck will supply pembrolizumab. IO Biotech maintains global commercial rights to IO102-IO103.
About IOB-022 / KN-D38
IOB-022 / KN-D38 is a non-comparative, open label trial to investigate the safety and efficacy of IO102-IO103 in combination with pembrolizumab in each of the following first-line indications: NSCLC, SCCHN, and mUBC. The clinical trial will be sponsored by IO Biotech and conducted in collaboration with Merck. IO Biotech maintains global commercial rights to IO102-IO103.
About IO102-IO103
IO102-IO103 is an investigational cancer immunotherapy designed to target the immunosuppressive mechanisms mediated by the key immunosuppressive proteins indoleamine 2,3-dehydrogenase (IDO) and PD-L1.
About IO Biotech
IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform. The T-win® platform is a novel approach to cancer immunotherapy designed to activate naturally occurring T cells to target immunosuppressive mechanisms. IO Biotech is advancing in clinical studies its lead immuno-oncology candidate, IO102-IO103, targeting IDO and PD-L1, and through clinical and preclinical development its other pipeline candidates. IO Biotech is headquartered in Copenhagen, Denmark and has additional offices within the United States (New York, New York and Rockville, Maryland) and United Kingdom (Monmouthshire).
For further information, please visit www.iobiotech.com
Forward-Looking Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including regarding future clinical trials, are based on IO Biotechs current assumptions and expectations of future events and trends, which affect or may affect its business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Except to the extent required by law, IO Biotech undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise.
Company Contact:
Mai-Britt Zocca, Ph.D.
President and CEO
IO Biotech, Inc.
mz@iobiotech.com
Investor Contact:
Corey Davis, Ph.D.
LifeSci Advisors
212-915-2577
cdavis@lifesciadvisors.com
Media Contact:
Raena Mina, Ph.D.
LifeSci Communications
646-606-1438
rmina@lifescicomms.com
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
tables to follow
IO BIOTECH, INC.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share amounts)
(unaudited)
For the Three Months Ended March 31, |
||||||||
2022 | 2021 | |||||||
Operating expenses |
||||||||
Research and development |
$ | 10,306 | $ | 2,848 | ||||
General and administrative |
6,704 | 965 | ||||||
|
|
|
|
|||||
Total operating expenses |
17,010 | 3,813 | ||||||
|
|
|
|
|||||
Loss from operations |
(17,010 | ) | (3,813 | ) | ||||
|
|
|
|
|||||
Other income (expense) |
||||||||
Currency exchange gain (loss), net |
(20 | ) | 137 | |||||
Interest income |
15 | | ||||||
Interest expense |
(123 | ) | (72 | ) | ||||
|
|
|
|
|||||
Total other income (expense), net |
(128 | ) | 65 | |||||
|
|
|
|
|||||
Loss before income tax expense |
(17,138 | ) | (3,748 | ) | ||||
Income tax expense |
66 | | ||||||
|
|
|
|
|||||
Net loss |
(17,204 | ) | (3,748 | ) | ||||
Cumulative dividends on class B and C preference shares |
| (1,839 | ) | |||||
|
|
|
|
|||||
Net loss attributable to common shareholders |
(17,204 | ) | (5,587 | ) | ||||
|
|
|
|
|||||
Net loss per common share, basic and diluted |
$ | (0.60 | ) | $ | (31.53 | ) | ||
|
|
|
|
|||||
Weighted-average number of shares used in computing net loss per common share, basic and diluted |
28,815,267 | 177,200 | ||||||
|
|
|
|
|||||
Other comprehensive loss |
||||||||
Net loss |
(17,204 | ) | (3,748 | ) | ||||
Foreign currency translation |
(2,647 | ) | (1,766 | ) | ||||
|
|
|
|
|||||
Total comprehensive loss |
(19,851 | ) | (5,514 | ) | ||||
|
|
|
|
See accompanying notes to the financial statements.
IO BIOTECH, INC.
Condensed Consolidated Balance Sheets
(In thousands, except share and per share amounts)
(unaudited)
March 31, 2022 |
December 31, 2021 |
|||||||
Assets |
||||||||
Current assets |
||||||||
Cash and cash equivalents |
$ | 187,904 | $ | 211,531 | ||||
Prepaid expenses and other current assets |
11,344 | 10,207 | ||||||
|
|
|
|
|||||
Total current assets |
199,248 | 221,738 | ||||||
Restricted cash |
268 | 268 | ||||||
Property and equipment, net |
271 | 155 | ||||||
Right of use lease asset |
2,248 | | ||||||
Noncurrent assets |
136 | 127 | ||||||
|
|
|
|
|||||
Total assets |
$ | 202,171 | $ | 222,288 | ||||
|
|
|
|
|||||
Liabilities, convertible preference shares and stockholders equity |
||||||||
Current liabilities |
||||||||
Accounts payable |
$ | 2,087 | $ | 3,928 | ||||
Lease liabilitycurrent |
345 | | ||||||
Accrued expenses and other current liabilities |
3,998 | 6,377 | ||||||
|
|
|
|
|||||
Total current liabilities |
6,430 | 10,305 | ||||||
Lease liabilitynoncurrent |
2,048 | | ||||||
Other long-term liabilities |
| 59 | ||||||
|
|
|
|
|||||
Total liabilities |
8,478 | 10,364 | ||||||
|
|
|
|
|||||
Commitments and contingencies (Note 9) |
||||||||
Convertible preference shares |
||||||||
Stockholders equity |
||||||||
Preferred stock, par value of $0.001 per share; 5,000,000 shares authorized, no shares issued and outstanding as of March 31, 2022 and December 31, 2021 |
| | ||||||
Common stock, par value of $0.001 per share; 300,000,000 shares authorized, 28,815,267 shares issued and outstanding as of March 31, 2022 and December 31, 2021 |
29 | 29 | ||||||
Additional paid-in capital |
321,285 | 319,665 | ||||||
Accumulated deficit |
(123,485 | ) | (106,281 | ) | ||||
Accumulated other comprehensive loss |
(4,136 | ) | (1,489 | ) | ||||
|
|
|
|
|||||
Total stockholders equity |
193,693 | 211,924 | ||||||
|
|
|
|
|||||
Total liabilities, convertible preference shares and stockholders equity |
$ | 202,171 | $ | 222,288 | ||||
|
|
|
|
See accompanying notes to the financial statements
IO Biotech ApS Ole Maaløes Vej 3 2200 Copenhagen N, Denmark www.iobiotech.com |
Page 5 of 5 |
Document and Entity Information |
May 16, 2022 |
---|---|
Cover [Abstract] | |
Amendment Flag | false |
Entity Central Index Key | 0001865494 |
Document Type | 8-K |
Document Period End Date | May 16, 2022 |
Entity Registrant Name | IO BIOTECH, INC. |
Entity Incorporation State Country Code | DE |
Entity File Number | 001-41008 |
Entity Tax Identification Number | 87-0909276 |
Entity Address, Address Line One | Ole Maaløes Vej 3 |
Entity Address, City or Town | DK-2200 Copenhagen N |
Entity Address, Postal Zip Code | DK-2200 |
Entity Address, Country | DK |
City Area Code | +45 |
Local Phone Number | 7070 2980 |
Written Communications | false |
Soliciting Material | false |
Pre Commencement Tender Offer | false |
Pre Commencement Issuer Tender Offer | false |
Security 12b Title | Common Stock, par value $0.001 per share |
Trading Symbol | IOBT |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | true |
Entity Ex Transition Period | false |
H_ 0 / ( \ ( !7! 'AL
M+W=O